Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Biocryst Pharmaceuticals (BCRX)
NASDAQ:BCRX
BCRX Stock Chart & Stats
Day’s Range― - ―
52-Week Range$4.03 - $9.48
Previous CloseN/A
Volume537.69K
Average Volume (3M)2.90M
Market Cap
$1.94B
Enterprise Value$2.08B
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)―
Beta0.78
Next Earnings
Feb 24, 2025EPS Estimate
-0.05Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.61
Shares Outstanding207,132,570
10 Day Avg. Volume3,534,505
30 Day Avg. Volume2,904,405
Standard Deviation0.21
R-Squared0.19
Alpha0.02
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)4.71
Price to Cash Flow (P/CF)59.00
P/FCF Ratio58.80
Enterprise Value/Market Cap1.07
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit6.38
Enterprise Value/Ebitda-75.54
Forecast
1Y Price Target
$13.20Price Target Upside43.32% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
---
BioCryst News
PremiumCompany Announcements
BioCryst to Present at J.P. Morgan Conference---
Bulls Say, Bears Say
Bulls Say
EarningsBioCryst reported preliminary 4Q24 Orladeyo sales of $124M with 2024 sales of $437M representing 34% Y/Y growth.
Financial PerformanceThe company's top-line is expected to grow at 20% CAGR through 2027, indicating strong future revenue growth.
Bears Say
CompetitionA competitor released a slide deck with a table comparing approved and in-development prophylactic therapies for hereditary angioedema (HAE), which suggested that Orladeyo’s efficacy was notably lower than that of other therapies.
---
Ownership Overview
6.71% Insiders
17.67% Mutual Funds
34.47% Other Institutional Investors
25.04% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
BCRX FAQ
What was Biocryst Pharmaceuticals’s price range in the past 12 months?
Biocryst Pharmaceuticals lowest stock price was $4.03 and its highest was $9.47 in the past 12 months.
What is Biocryst Pharmaceuticals’s market cap?
Biocryst Pharmaceuticals’s market cap is $1.94B.
When is Biocryst Pharmaceuticals’s upcoming earnings report date?
Biocryst Pharmaceuticals’s upcoming earnings report date is Feb 24, 2025 which is in 2 days.
How were Biocryst Pharmaceuticals’s earnings last quarter?
Biocryst Pharmaceuticals released its earnings results on Nov 04, 2024. The company reported -$0.07 earnings per share for the quarter, missing the consensus estimate of -$0.068 by -$0.002.
Is Biocryst Pharmaceuticals overvalued?
According to Wall Street analysts Biocryst Pharmaceuticals’s price is currently Undervalued.
Does Biocryst Pharmaceuticals pay dividends?
Biocryst Pharmaceuticals does not currently pay dividends.
What is Biocryst Pharmaceuticals’s EPS estimate?
Biocryst Pharmaceuticals’s EPS estimate is -0.05.
How many shares outstanding does Biocryst Pharmaceuticals have?
Biocryst Pharmaceuticals has 207,132,570 shares outstanding.
What happened to Biocryst Pharmaceuticals’s price movement after its last earnings report?
Biocryst Pharmaceuticals reported an EPS of -$0.07 in its last earnings report, missing expectations of -$0.068. Following the earnings report the stock price went down -12.811%.
Which hedge fund is a major shareholder of Biocryst Pharmaceuticals?
Currently, no hedge funds are holding shares in BCRX
---
BioCryst Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$13.20 (43.32% Upside)
$13.20 (43.32% Upside)
Blogger Sentiment
Bullish
BCRX Sentiment 85%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Increased
By 255.9K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Positive
Last 7 Days ▲ 0.7%
Last 30 Days ▲ 0.7%
Last 30 Days ▲ 0.7%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
61.34%
12-Months-Change
Fundamentals
Return on Equity
26.42%
Trailing 12-Months
Asset Growth
-6.06%
Trailing 12-Months
Company Description
Biocryst Pharmaceuticals
BioCryst Pharmaceuticals, Inc. designs, optimizes and develops novel small molecule drugs that block key enzymes involved in the pathogenesis of diseases. Its drug candidates include rapivab, alpivab, rapiacta, peramiflu, BCX7353, BCX9930, BCX9250, Galidesivir, and Mundesine. The company was founded in 1986 and is headquartered in Durham, NC.
---
BCRX Company Deck
---
BCRX Earnings Call
Q3 2024
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call highlighted strong revenue growth for Orladeyo, successful addition of new prescribers, and significant progress in clinical trials and financial performance, indicating positive momentum. However, challenges remain with the Medicare paid rate and potential royalty impacts. Overall, the positive developments significantly outweigh the challenges.Read More>---
BCRX Stock 12 Month Forecast
Average Price Target
$13.20
▲(43.32% Upside)
Technical Analysis
Alnylam Pharma
―
BioMarin Pharmaceutical
―
Regeneron
―
Vertex Pharmaceuticals
―
Bluebird Bio
―
Best Analysts Covering BCRX
1 Year
1 Year Success Rate
11/21 ratings generated profit
1 Year Average Return
+6.50%
reiterated a buy rating last month
Copying Liisa Bayko's trades and holding each position for 1 Year would result in 52.38% of your transactions generating a profit, with an average return of +6.50% per trade.
---